export const referencesData = {
  "58": {
    text: "Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst. 1996 Jul 3;88(13):918–22.",
    url: "https://doi.org/10.1093/jnci/88.13.918"
  },
  "80": {
    text: "Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023 Feb;22(2):101–26.",
    url: "https://doi.org/10.1038/s41573-022-00595-0"
  },
  "81": {
    text: "Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, et al. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol. 2024 Feb 1;25(2):e73–83.",
    url: "https://doi.org/10.1016/S1470-2045(23)00534-X"
  },
  "116": {
    text: "Borel C, Sun XS, Coutte A, Bera G, Sire C, Zanetta S, et al. Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial. Radiother Oncol. 2024 Aug 1;197.",
    url: "https://doi.org/10.1016/j.radonc.2024.109962"
  },
  "162": {
    text: "Ivaldi GB, Leonardi M, Ferrari A, Morra A, Fossati BJ, Vavassori A, et al. Concomitant Radiotherapy and Anthracycline-based Chemotherapy in Adjuvant Breast Cancer Treatment. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):S180–1.",
    url: "https://www.redjournal.org/article/S0360-3016(08)01392-8/fulltext"
  },
  "164": {
    text: "Spittle MF. Methotrexate and radiation. Int J Radiat Oncol. 1978 Jan 1;4(1):103–7.",
    url: "https://doi.org/10.1016/0360-3016(78)90123-2"
  },
  "170": {
    text: "Peters NAJB, Richel DJ, Verhoeff JJC, Stalpers LJA. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol Off J Am Soc Clin Oncol. 2008 May 10;26(14):2405–6.",
    url: "https://doi.org/10.1200/jco.2007.15.8451"
  },
  "171": {
    text: "Guimond E, Tsai CJ, Hosni A, O'Kane G, Yang J, Barry A. Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies. Adv Radiat Oncol. 2022 Jul 14;7(6):101022.",
    url: "https://doi.org/10.1016/j.adro.2022.101022"
  },
  "178": {
    text: "Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):632–46.",
    url: "https://doi.org/10.1016/j.ijrobp.2016.01.038"
  },
  "184": {
    text: "Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, et al. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. JAMA Oncol. 2022 Dec 1;8(12):1802–8.",
    url: "https://doi.org/10.1001/jamaoncol.2022.5074"
  },
  "185": {
    text: "Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Res. 1989 Feb 1;49(3):605–12.",
    url: "https://doi.org/10.1073/pnas.86.13.4963"
  },
  "186": {
    text: "Einhorn L, Krause M, Hornback N, Furnas B. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer. 1976 May;37(5):2414–6.",
    url: "https://doi.org/10.1002/1097-0142(197605)37:5%3C2414::aid-cncr2820370533%3E3.0.co;2-j"
  },
  "187": {
    text: "Vermund H, Kaalhus O, Winther F, Trausjø J, Thorud E, Harang R. Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: A phase III clinical trial. Int J Radiat Oncol Biol Phys. 1985 Nov 1;11(11):1877–86.",
    url: "https://doi.org/10.1016/0360-3016(85)90267-6"
  },
  "188": {
    text: "Matsuoka K, Kobunai T, Nukatsuka M, Takechi T. Improved chemoradiation treatment using trifluridine in human colorectal cancer cells in vitro. Biochem Biophys Res Commun. 2017 Dec 9;494(1–2):249–55.",
    url: "https://doi.org/10.1016/j.bbrc.2017.10.052"
  },
  "189": {
    text: "Thiele B, Stein A, Schultheiß C, Paschold L, Jonas H, Goekkurt E, et al. Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial. Clin Colorectal Cancer. 2024 Jun 22",
    url: "https://doi.org/10.1016/j.clcc.2024.06.003"
  },
  "190": {
    text: "Arrieta O, Gallardo-Rincón D, Villarreal-Garza C, Michel RM, Astorga-Ramos AM, Martinez-Barrera L, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009 Jul;4(7):845–52.",
    url: "https://doi.org/10.1097/jto.0b013e3181a97e17"
  },
  "191": {
    text: "Iglseder S, Nowosielski M, Bsteh G, Muigg A, Heugenhauser J, Mayer E, et al. Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis-a safety analysis and validation of the EANO-ESMO classification. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2022 May;198(5):475–83.",
    url: "https://doi.org/10.1007/s00066-022-01910-9"
  },
  "192": {
    text: "Choy H, Gerber DE, Bradley JD, Iyengar P, Monberg M, Treat J, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer Amst Neth. 2015 Mar;87(3):232–40.",
    url: "https://doi.org/10.1016/j.lungcan.2014.12.003"
  },
  "193": {
    text: "Botwood N, James R, Vernon C, Price P. Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2000 Aug;11(8):1023–8.",
    url: "https://doi.org/10.1023/a:1008376306429"
  },
  "194": {
    text: "Martin DS, Kligerman MM, Fugmann RA. Radiotherapy and Adjuvant Combination Chemotherapy (6-Aminonicotinamide and 6-Mercaptopurine). Cancer Res. 1958 Sep 1;18(8_Part_1):893–6.",
    url: "https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://pubmed.ncbi.nlm.nih.gov/13573360/&ved=2ahUKEwi66uilyNqLAxXLTKQEHYyIMIEQFnoECBUQAQ&usg=AOvVaw2wTIX5ZRNpb3igjNM0nOz7"
  },
  "195": {
    text: "Nitsche M, Christiansen H, Lederer K, Griesinger F, Schmidberger H, Pradier O. Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study. J Cancer Res Clin Oncol. 2012 Jul;138(7):1113–20.",
    url: "https://doi.org/10.1007/s00432-012-1185-3"
  },
  "196": {
    text: "Solomon SR, Solh M, Zhang X, Morris LE, Holland HK, Bashey A. Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019 Nov;25(11):2211–6.",
    url: "https://doi.org/10.1016/j.bbmt.2019.06.017"
  },
  "197": {
    text: "Cariveau MJ, Stackhouse M, Cui XL, Tiwari K, Waud W, Secrist JA, et al. Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):213–20.",
    url: "https://doi.org/10.1016/j.ijrobp.2007.09.012"
  },
  "198": {
    text: "El Cheikh J, Bidaoui G, Atoui A, Terro K, Sharrouf L, Zahreddine A, et al. Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study. Bone Marrow Transplant. 2023 Jun;58(6):667–72.",
    url: "https://www.nature.com/articles/s41409-023-01947-z#citeas"
  },
  "199": {
    text: "Hetzel FW, Brown M, Kaufman N, Bicher HI. Radiation sensitivity modification by chemotherapeutic agents. Cancer Clin Trials. 1981;4(2):177–82.",
    url: "https://pubmed.ncbi.nlm.nih.gov/7249254/"
  },
  "200": {
    text: "Cailleteau A, Maingon P, Choquet S, Bourdais R, Antoni D, Lioure B, et al. Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m2) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):677–85.",
    url: "https://doi.org/10.1016/j.ijrobp.2022.09.069"
  },
  "201": {
    text: "Zachariae C, Overgaard J. Interactions of radiation, cyclophosphamide and nimorazole in a C3H mammary carcinoma in vivo. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1445–8.",
    url: "https://doi.org/10.1016/0360-3016(86)90191-4"
  },
  "202": {
    text: "Byar D, Kenis Y, Van Andel JG, de Jong M, Laval P, Marion L, et al. Results of a E.O.R.T.C. randomized trial of cyclophosphamide and radiotherapy in inoperable lung cancer: Prognostic factors and treatment results. Eur J Cancer 1965. 1978 Sep 1;14(9):919–30.",
    url: "https://doi.org/10.1016/0014-2964(78)90018-x"
  },
  "203": {
    text: "Eckert F, Matuschek C, Mueller AC, Weinmann M, Hartmann JT, Belka C, et al. Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiat Oncol Lond Engl. 2010 Jun 16;5:55.",
    url: "https://doi.org/10.1186/1748-717x-5-55"
  },
  "204": {
    text: "Spalek MJ, Koseła-Paterczyk H, Borkowska A, Wagrodzki M, Szumera-Cieckiewicz A, Czarnecka AM, et al. Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. Int J Radiat Oncol. 2021 Jul 15;110(4):1053–63.",
    url: "https://doi.org/10.1016/j.ijrobp.2021.02.019"
  },
  "205": {
    text: "Nahi H, Svedmyr E, Lerner R. Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement. Eur J Haematol. 2014;92(5):454–5.",
    url: "https://doi.org/10.1111/ejh.12247"
  },
  "206": {
    text: "Pan E, Yu D, Zhao X, Neuger A, Smith P, Chinnaiyan P, et al. Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. J Neurooncol. 2014 Sep;119(2):413–20.",
    url: "https://doi.org/10.1007/s11060-014-1510-6"
  },
  "207": {
    text: "Arcicasa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovò MG. Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):789–93.",
    url: "https://doi.org/10.1016/s0360-3016(98)00457-x"
  },
  "208": {
    text: "Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. J Clin Oncol. 2006 Sep 20;24(27):4412–7.",
    url: "https://doi.org/10.1200/jco.2006.06.9104"
  },
  "209": {
    text: "Sanfilippo R, Hindi N, Cruz Jurado J, Blay JY, Lopez-Pousa A, Italiano A, et al. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2023 May 1;9(5):656–63.",
    url: "https://doi.org/10.1001/jamaoncol.2023.0056"
  },
  "210": {
    text: "Martin-Broto J, Hindi N, Lopez-Pousa A, Peinado-Serrano J, Alvarez R, Alvarez-Gonzalez A, et al. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. JAMA Oncol. 2020 Apr 1;6(4):535–41.",
    url: "https://jamanetwork.com/journals/jamaoncology/fullarticle/2761664"
  },
  "211": {
    text: "Meattini I, Desideri I, Di Cataldo V, Francolini G, De Luca Cardillo C, Scotti V, et al. Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience and review of the literature. Future Oncol Lond Engl. 2016 May;12(9):1117–24.",
    url: "https://doi.org/10.2217/fon-2015-0059"
  },
  "212": {
    text: "Salama MM, Ghorab EM, Al-Abyad AG, Al-Bahy KM. Concomitant weekly vincristine and radiation followed by adjuvant vincristine and carboplatin in the treatment of high risk medulloblastoma: Ain Shams University Hospital and Sohag Cancer Center study. J Egypt Natl Cancer Inst. 2006 Jun;18(2):167–74.",
    url: "https://pubmed.ncbi.nlm.nih.gov/17496943/"
  },
  "213": {
    text: "Singhal N, Mislang A, Karapetis CS, Stephens S, Borg M, Woodman RJ, et al. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer: an open-label phase II multicentre trial (COVeRT study). Anticancer Drugs. 2015 Nov;26(10):1083–8.",
    url: "https://doi.org/10.1159/000092062"
  },
  "214": {
    text: "Arnold CR, Lindner AK, Schachtner G, Tulchiner G, Tulchiner N, Mangesius J, et al. Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer-a valid option for cisplatin-unfit patients? Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al. 2022 Jan;198(1):25–32.",
    url: "https://doi.org/10.1007/s00066-021-01837-7"
  },
  "215": {
    text: "Nguyen PL, Kollmeier M, Rathkopf DE, Hoffman KE, Zurita AJ, Spratt DE, et al. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).",
    url: "https://doi.org/10.1200/JCO.2023.41.6_suppl.303"
  },
  "216": {
    text: "Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, et al. Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.",
    url: "https://doi.org/10.1016/j.euo.2024.06.013"
  },
  "217": {
    text: "Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, et al. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.",
    url: "https://doi.org/10.1200/jco.22.01662"
  },
  "218": {
    text: "Sargos P, Bellera C, Bentahila R, Guerni M, Benziane-Ouaritini N, Teyssonneau D, et al. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol.",
    url: "https://doi.org/10.1016/j.euo.2024.04.023"
  },
  "219": {
    text: "Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer.",
    url: "https://doi.org/10.1016/s0140-6736(21)02437-5"
  },
  "220": {
    text: "Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).",
    url: "https://doi.org/10.1200/jco.23.00985"
  },
  "221": {
    text: "Wang J, Yang Q, Haffty BG, Li X, Moran MS. Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells. Biochem Biophys Res Commun. 2013 Feb 8;431(2):146–51.",
    url: "https://doi.org/10.1016/j.bbrc.2013.01.006"
  },
  "222": {
    text: "Ding J, Guo Y, Jiang X, Li K, Fu W, Cao Y. Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer.",
    url: "https://doi.org/10.1097/MD.0000000000021344"
  },
  "223": {
    text: "Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.",
    url: "https://doi.org/10.1016/s1470-2045(10)70013-9"
  },
  "224": {
    text: "Eze C, Hegemann NS, Roengvoraphoj O, Dantes M, Manapov F. Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature. Front Oncol. 2017;7:88.",
    url: "https://doi.org/10.3389/fonc.2017.00088"
  },
  "225": {
    text: "Occhipinti M, Falcone R, Onesti CE, Botticelli A, Mazzuca F, Marchetti P, et al. Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. J Thorac Dis. 2017 Nov;9(11):E985–9.",
    url: "https://doi.org/10.21037/jtd.2017.09.74"
  },
  "226": {
    text: "Dai Y, Wei Q, Schwager C, Moustafa M, Zhou C, Lipson KE, et al. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.",
    url: "https://doi.org/10.1016/j.radonc.2014.12.009"
  },
  "227": {
    text: "Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.",
    url: "https://doi.org/10.1016/j.ijrobp.2013.11.010"
  },
  "228": {
    text: "Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.",
    url: "https://doi.org/10.1158/1078-0432.ccr-13-0306"
  },
  "229": {
    text: "Stagno F, Vigneri P, Fabro VD, Stella S, Restuccia N, Giallongo C, et al. Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.",
    url: "https://doi.org/10.3109/02841860903302913"
  },
  "230": {
    text: "Joensuu H, Eriksson M, Collan J, Balk MH, Leyvraz S, Montemurro M. Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.",
    url: "https://doi.org/10.1016/j.radonc.2015.07.025"
  },
  "231": {
    text: "Cote GM, Barysauskas CM, DeLaney TF, Schwab J, Raskin K, Lozano-Calderon S, et al. A Phase 1 Study of Nilotinib Plus Radiation in High-Risk Chordoma.",
    url: "https://doi.org/10.1016/j.ijrobp.2018.07.2013"
  },
  "232": {
    text: "Tan B, Huang Y, Zhang B, Lin N. The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR/AKT/mTOR signaling pathway. Biomed Pharmacother Biomedecine Pharmacother. 2020 Aug;128:110133.",
    url: "https://doi.org/10.1016/j.biopha.2020.110133"
  },
  "233": {
    text: "De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L, et al. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.",
    url: "https://doi.org/10.1186/s13014-017-0893-x"
  },
  "234": {
    text: "Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH, et al. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer: a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.",
    url: "https://doi.org/10.1016/S1470-2045(22)00763-X"
  },
  "235": {
    text: "Eze C, Hegemann NS, Roengvoraphoj O, Dantes M, Manapov F. Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature. Front Oncol. 2017;7:88.",
    url: "https://doi.org/10.3389/fonc.2017.00088"
  },
